Devalued and distrusted: can the pharmaceutical industry restore its broken image?
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Hoboken, New Jersey
Wiley
[2013]
|
| Schlagworte: | |
| Online-Zugang: | FRO01 UBG01 Volltext |
| Beschreibung: | Includes index. - Machine generated contents note: Introduction Part 1. "The 4 secrets that drug companies don't want you to know" part 2. What has happened to R & D productivity? a. impact of mergers b. impact of FDA c. impact of payers Part 3. Challenges in key therapeutic areas for improving health a. cancer b. diseases of the brain c. cardiovascular disease d. diabetes e. bacterial Infections part 4. Improving R & D output a. view of others b. personal vision part 5. Restoring the pharma image part 6. Final thoughts "While the pharmaceutical industry can play an important role in converting the knowledge generated by the Human Genome Project into new medicines, it also faces a popular perception that it is simply out to make money by promoting unsafe medicines to an unsuspecting public. Written by former Pfizer president John LaMattina, this book addresses the progress that the industry has made in improving its abilities to measure both the risk and benefits of its new medicines, where the industry should invest its R & D resources, and how the industry can rehabilitate its image. Essential reading for pharmaceutical executives and professionals"-- Includes bibliographical references and index |
| Beschreibung: | 1 Online-Ressource (ix, 125 pages) |
| ISBN: | 9781283917421 1283917424 9781118511251 1118511255 9781118511299 1118511298 9781118511329 1118511328 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV043395679 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 160222s2013 |||| o||u| ||||||eng d | ||
| 020 | |a 9781283917421 |c MyiLibrary |9 978-1-283-91742-1 | ||
| 020 | |a 1283917424 |c MyiLibrary |9 1-283-91742-4 | ||
| 020 | |a 9781118511251 |c electronic bk. |9 978-1-118-51125-1 | ||
| 020 | |a 1118511255 |c electronic bk. |9 1-118-51125-5 | ||
| 020 | |a 9781118511299 |c electronic bk. |9 978-1-118-51129-9 | ||
| 020 | |a 1118511298 |c electronic bk. |9 1-118-51129-8 | ||
| 020 | |a 9781118511329 |c electronic bk. |9 978-1-118-51132-9 | ||
| 020 | |a 1118511328 |c electronic bk. |9 1-118-51132-8 | ||
| 024 | 7 | |a 10.1002/9781118511329 |2 doi | |
| 035 | |a (ZDB-35-WIC)ocn831464032 | ||
| 035 | |a (OCoLC)831464032 | ||
| 035 | |a (DE-599)BVBBV043395679 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-861 | ||
| 082 | 0 | |a 338.4/76151 |2 23 | |
| 100 | 1 | |a LaMattina, John L. |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Devalued and distrusted |b can the pharmaceutical industry restore its broken image? |c John L. LaMattina, PhD. |
| 264 | 1 | |a Hoboken, New Jersey |b Wiley |c [2013] | |
| 300 | |a 1 Online-Ressource (ix, 125 pages) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Includes index. - Machine generated contents note: Introduction Part 1. "The 4 secrets that drug companies don't want you to know" part 2. What has happened to R & D productivity? a. impact of mergers b. impact of FDA c. impact of payers Part 3. Challenges in key therapeutic areas for improving health a. cancer b. diseases of the brain c. cardiovascular disease d. diabetes e. bacterial Infections part 4. Improving R & D output a. view of others b. personal vision part 5. Restoring the pharma image part 6. Final thoughts | ||
| 500 | |a "While the pharmaceutical industry can play an important role in converting the knowledge generated by the Human Genome Project into new medicines, it also faces a popular perception that it is simply out to make money by promoting unsafe medicines to an unsuspecting public. Written by former Pfizer president John LaMattina, this book addresses the progress that the industry has made in improving its abilities to measure both the risk and benefits of its new medicines, where the industry should invest its R & D resources, and how the industry can rehabilitate its image. Essential reading for pharmaceutical executives and professionals"-- | ||
| 500 | |a Includes bibliographical references and index | ||
| 650 | 4 | |a Medical | |
| 650 | 7 | |a MEDICAL / Pharmacology |2 bisacsh | |
| 650 | 7 | |a Pharmaceutical industry / Corrupt practices |2 fast | |
| 650 | 4 | |a Medizin | |
| 650 | 4 | |a Pharmaceutical industry / Corrupt practices | |
| 653 | |a Electronic books | ||
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe, Paperback |z 978-1-118-48747-1 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe, Paperback |z 1-118-48747-8 |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/book/10.1002/9781118511329 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-35-WIC | ||
| 940 | 1 | |q UBG_PDA_WIC | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-028814263 | ||
| 966 | e | |u https://onlinelibrary.wiley.com/doi/book/10.1002/9781118511329 |l FRO01 |p ZDB-35-WIC |q FRO_PDA_WIC |x Verlag |3 Volltext | |
| 966 | e | |u https://onlinelibrary.wiley.com/doi/book/10.1002/9781118511329 |l UBG01 |p ZDB-35-WIC |q UBG_PDA_WIC |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804175975774158848 |
|---|---|
| any_adam_object | |
| author | LaMattina, John L. |
| author_facet | LaMattina, John L. |
| author_role | aut |
| author_sort | LaMattina, John L. |
| author_variant | j l l jl jll |
| building | Verbundindex |
| bvnumber | BV043395679 |
| collection | ZDB-35-WIC |
| ctrlnum | (ZDB-35-WIC)ocn831464032 (OCoLC)831464032 (DE-599)BVBBV043395679 |
| dewey-full | 338.4/76151 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 338 - Production |
| dewey-raw | 338.4/76151 |
| dewey-search | 338.4/76151 |
| dewey-sort | 3338.4 576151 |
| dewey-tens | 330 - Economics |
| discipline | Wirtschaftswissenschaften |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03466nmm a2200565zc 4500</leader><controlfield tag="001">BV043395679</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">160222s2013 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781283917421</subfield><subfield code="c">MyiLibrary</subfield><subfield code="9">978-1-283-91742-1</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1283917424</subfield><subfield code="c">MyiLibrary</subfield><subfield code="9">1-283-91742-4</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781118511251</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">978-1-118-51125-1</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1118511255</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">1-118-51125-5</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781118511299</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">978-1-118-51129-9</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1118511298</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">1-118-51129-8</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781118511329</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">978-1-118-51132-9</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1118511328</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">1-118-51132-8</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1002/9781118511329</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-35-WIC)ocn831464032</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)831464032</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043395679</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-861</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">338.4/76151</subfield><subfield code="2">23</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">LaMattina, John L.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Devalued and distrusted</subfield><subfield code="b">can the pharmaceutical industry restore its broken image?</subfield><subfield code="c">John L. LaMattina, PhD.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Hoboken, New Jersey</subfield><subfield code="b">Wiley</subfield><subfield code="c">[2013]</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (ix, 125 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes index. - Machine generated contents note: Introduction Part 1. "The 4 secrets that drug companies don't want you to know" part 2. What has happened to R & D productivity? a. impact of mergers b. impact of FDA c. impact of payers Part 3. Challenges in key therapeutic areas for improving health a. cancer b. diseases of the brain c. cardiovascular disease d. diabetes e. bacterial Infections part 4. Improving R & D output a. view of others b. personal vision part 5. Restoring the pharma image part 6. Final thoughts</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">"While the pharmaceutical industry can play an important role in converting the knowledge generated by the Human Genome Project into new medicines, it also faces a popular perception that it is simply out to make money by promoting unsafe medicines to an unsuspecting public. Written by former Pfizer president John LaMattina, this book addresses the progress that the industry has made in improving its abilities to measure both the risk and benefits of its new medicines, where the industry should invest its R & D resources, and how the industry can rehabilitate its image. Essential reading for pharmaceutical executives and professionals"--</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medical</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Pharmacology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmaceutical industry / Corrupt practices</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical industry / Corrupt practices</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Electronic books</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe, Paperback</subfield><subfield code="z">978-1-118-48747-1</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe, Paperback</subfield><subfield code="z">1-118-48747-8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://onlinelibrary.wiley.com/doi/book/10.1002/9781118511329</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-35-WIC</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">UBG_PDA_WIC</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028814263</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://onlinelibrary.wiley.com/doi/book/10.1002/9781118511329</subfield><subfield code="l">FRO01</subfield><subfield code="p">ZDB-35-WIC</subfield><subfield code="q">FRO_PDA_WIC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://onlinelibrary.wiley.com/doi/book/10.1002/9781118511329</subfield><subfield code="l">UBG01</subfield><subfield code="p">ZDB-35-WIC</subfield><subfield code="q">UBG_PDA_WIC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV043395679 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:24:50Z |
| institution | BVB |
| isbn | 9781283917421 1283917424 9781118511251 1118511255 9781118511299 1118511298 9781118511329 1118511328 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-028814263 |
| oclc_num | 831464032 |
| open_access_boolean | |
| owner | DE-861 |
| owner_facet | DE-861 |
| physical | 1 Online-Ressource (ix, 125 pages) |
| psigel | ZDB-35-WIC UBG_PDA_WIC ZDB-35-WIC FRO_PDA_WIC ZDB-35-WIC UBG_PDA_WIC |
| publishDate | 2013 |
| publishDateSearch | 2013 |
| publishDateSort | 2013 |
| publisher | Wiley |
| record_format | marc |
| spelling | LaMattina, John L. Verfasser aut Devalued and distrusted can the pharmaceutical industry restore its broken image? John L. LaMattina, PhD. Hoboken, New Jersey Wiley [2013] 1 Online-Ressource (ix, 125 pages) txt rdacontent c rdamedia cr rdacarrier Includes index. - Machine generated contents note: Introduction Part 1. "The 4 secrets that drug companies don't want you to know" part 2. What has happened to R & D productivity? a. impact of mergers b. impact of FDA c. impact of payers Part 3. Challenges in key therapeutic areas for improving health a. cancer b. diseases of the brain c. cardiovascular disease d. diabetes e. bacterial Infections part 4. Improving R & D output a. view of others b. personal vision part 5. Restoring the pharma image part 6. Final thoughts "While the pharmaceutical industry can play an important role in converting the knowledge generated by the Human Genome Project into new medicines, it also faces a popular perception that it is simply out to make money by promoting unsafe medicines to an unsuspecting public. Written by former Pfizer president John LaMattina, this book addresses the progress that the industry has made in improving its abilities to measure both the risk and benefits of its new medicines, where the industry should invest its R & D resources, and how the industry can rehabilitate its image. Essential reading for pharmaceutical executives and professionals"-- Includes bibliographical references and index Medical MEDICAL / Pharmacology bisacsh Pharmaceutical industry / Corrupt practices fast Medizin Pharmaceutical industry / Corrupt practices Electronic books Erscheint auch als Druck-Ausgabe, Paperback 978-1-118-48747-1 Erscheint auch als Druck-Ausgabe, Paperback 1-118-48747-8 https://onlinelibrary.wiley.com/doi/book/10.1002/9781118511329 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | LaMattina, John L. Devalued and distrusted can the pharmaceutical industry restore its broken image? Medical MEDICAL / Pharmacology bisacsh Pharmaceutical industry / Corrupt practices fast Medizin Pharmaceutical industry / Corrupt practices |
| title | Devalued and distrusted can the pharmaceutical industry restore its broken image? |
| title_auth | Devalued and distrusted can the pharmaceutical industry restore its broken image? |
| title_exact_search | Devalued and distrusted can the pharmaceutical industry restore its broken image? |
| title_full | Devalued and distrusted can the pharmaceutical industry restore its broken image? John L. LaMattina, PhD. |
| title_fullStr | Devalued and distrusted can the pharmaceutical industry restore its broken image? John L. LaMattina, PhD. |
| title_full_unstemmed | Devalued and distrusted can the pharmaceutical industry restore its broken image? John L. LaMattina, PhD. |
| title_short | Devalued and distrusted |
| title_sort | devalued and distrusted can the pharmaceutical industry restore its broken image |
| title_sub | can the pharmaceutical industry restore its broken image? |
| topic | Medical MEDICAL / Pharmacology bisacsh Pharmaceutical industry / Corrupt practices fast Medizin Pharmaceutical industry / Corrupt practices |
| topic_facet | Medical MEDICAL / Pharmacology Pharmaceutical industry / Corrupt practices Medizin |
| url | https://onlinelibrary.wiley.com/doi/book/10.1002/9781118511329 |
| work_keys_str_mv | AT lamattinajohnl devaluedanddistrustedcanthepharmaceuticalindustryrestoreitsbrokenimage |